糖尿病性神経障害市場：治療タイプ、疾患タイプ、流通チャネル別-世界予測2024-2030年

糖尿病性神経障害市場規模は2023年に35億米ドルと推計され、2024年には37億2,000万米ドルに達し、CAGR 6.37%で2030年には54億米ドルに達すると予測されます。

糖尿病性神経障害は神経を損傷する病状で、糖尿病患者に発症します。高血糖（グルコース）は全身の神経を損傷しますが、糖尿病性神経障害は足腰の神経に最も頻繁に影響を及ぼします。糖尿病性神経障害の効果的な治療に対するニーズの高まり、糖尿病の診断、いくつかの政府の取り組みが、糖尿病性神経障害市場成長の主な促進要因です。さらに、糖尿病性神経障害に対する意識の高まり、ヘルスケア支出の増加、医薬品研究開発費の増加は、糖尿病性神経障害を治療するための新薬やシステムの開発に貢献しています。しかし、糖尿病性神経障害の治療に使用される薬剤は高価であり、代替療法が利用可能であるため、糖尿病患者による使用が制限される可能性があります。先進的なドラッグデリバリーシステムの生産と糖尿病性神経障害の研究の高まりは、糖尿病性神経障害の状態を効果的に管理する画期的なシステムの開発につながり、予測期間中に患者による使用を加速させる。

治療タイプ糖尿病性神経障害の薬理学的治療では、疼痛緩和と神経機能安定化のために薬剤が広く使用されている

糖尿病性神経障害の薬物療法では、疼痛の緩和や神経機能の安定を目的として薬剤が使用されています。プレガバリン（リリカ）とガバペンチン（ニューロンチン）は、糖尿病性神経障害患者の神経痛管理によく使われる抗けいれん薬です。オピオイドの中では、Tramadol（Ultram）が糖尿病性神経障害に関連した中等度から重度の疼痛に処方される中枢作動性オピオイド鎮痛薬です。理学療法としても知られるフィジオセラピーは、糖尿病性神経障害患者の機能的能力を向上させ、痛みを和らげる非薬物療法です。認定理学療法士が監督する定期的な運動や筋力強化プログラムは、糖尿病性神経障害患者の筋力、バランス、持久力の向上に役立ちます。副作用や禁忌を避けるために、理学療法が好まれることが多いです。

障害の種類末梢神経障害の有病率の増加による糖尿病性神経障害の優先順位

自律神経障害は、内臓の不随意機能を制御する自律神経系に影響を及ぼします。この疾患の患者は、不整脈、排尿障害、消化器系の問題、性機能障害を経験します。個々のニーズに応じて、治療には血圧や心拍数を調整する薬、消化管運動に対する薬、勃起不全を治療する薬などが用いられます。局所神経障害とは、1本の神経または1群の神経が障害され、手、足、胴体など身体の特定の部位に限局した激しい痛みや脱力を引き起こす疾患です。治療は、手根管症候群に対するスプリントや装具、重症例に対する外科的介入など、圧迫や巻き込みなどの根本的な原因に対処します。末梢神経障害は最も一般的なタイプで、腕、手、足、脚の神経に影響を及ぼします。症状としては、しびれ、ピリピリ感、痛み、脱力感などがあります。市販の鎮痛薬や処方薬など、治療法は個々のニーズによって異なります。近位神経障害では、主に臀部、臀部、大腿部の筋肉が侵され、激しい痛みや筋力低下などの症状がみられます。

流通経路：糖尿病性神経障害管理のために処方される薬の便利な流通経路としてのオンライン薬局の出現

糖尿病性神経障害患者は、内分泌専門医、足病専門医、糖尿病教育者などの専門家チームによる専門的治療を提供するクリニックを、利便性、手ごろな価格、アクセスの良さから好みます。病院は、感染症や潰瘍などの重篤な合併症により、より広範な治療や緊急介入を必要とする糖尿病性神経障害患者のための包括的なケアプロバイダーとしての役割を果たします。病院では、複雑な症例の治療に精通した機器や集学的チームを利用することができます。オンライン薬局は、疼痛緩和薬、抗痙攣薬、抗うつ薬など、糖尿病性神経障害管理のために処方される医薬品の便利な流通経路として台頭してきました。オンライン薬局は、小売薬局に比べて使いやすく、配送方法も控えめで、価格も競争力があるため、患者から好まれています。小売薬局は、糖尿病性神経障害を管理するための薬や市販のサプリメントを入手するのに人気があります。小売薬局では、薬剤師と直接対面することができるため、一人ひとりに合ったアドバイスや服薬管理のサポートを受けることができ、幅広い商品を入手できるという利点があります。

地域別インサイト

南北アメリカは、糖尿病患者の増加と糖尿病疾患に対する意識の高まりにより、糖尿病性神経障害の重要な市場となっています。FDAによる新製品開発の承認と、新規かつ効果的な医薬品開発のための継続的な研究活動は、南北アメリカ地域の主要な成長要因です。アジア太平洋地域は、医薬品開発における研究開発活動の活発化により、世界の糖尿病性神経障害市場の成長を象徴しています。APAC地域では、糖尿病性神経障害治療薬の開発に注力している新興企業がいくつかあり、市場の成長に寄与しています。糖尿病管理に関する意識を高めるための政府支援や、疼痛緩和や糖尿病性神経障害症状の効率的な管理のための新規薬剤やシステムの研究開発の増加は、EMEA地域における糖尿病性神経障害薬剤やシステムの展開に大きな可能性をもたらしています。さらに、革新的な治療法やドラッグデリバリーシステムの導入が、糖尿病性神経障害市場の世界の成長に貢献すると期待されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは糖尿病性神経障害市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、糖尿病性神経障害市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.糖尿病性神経障害市場の市場規模および予測は？

2.糖尿病性神経障害市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.糖尿病性神経障害市場の技術動向と規制枠組みは？

4.糖尿病性神経障害市場における主要ベンダーの市場シェアは？

5.糖尿病性神経障害市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 糖尿病性神経障害の蔓延と効果的な治療法の必要性
    • 糖尿病の診断と治療に関する意識の向上
    • 糖尿病性神経障害の管理に関する政府の取り組み
  • 抑制要因
    • 臨床試験の失敗率が高く、治療費も高額
  • 機会
    • 糖尿病性神経障害調査領域の拡大
    • 先進的なドラッグデリバリーシステムの開発
  • 課題
    • 糖尿病性神経障害治療に伴う合併症
• 市場セグメンテーション分析
  • 治療タイプ：痛みを和らげ、神経機能を安定させるための薬物療法における薬物の広範な使用
  • 障害の種類：末梢神経障害の有病率の増加により、糖尿病性神経障害が優先されます
  • 流通チャネル：医療用医薬品の便利な流通チャネルとしてのオンライン薬局の出現
• 市場動向分析
  • 南北アメリカにおける新たな治療法の開発と糖尿病性神経障害管理システムの承認増加に向けた継続的な調査
  • 糖尿病の罹患率の増加と、アジア太平洋地域での治療法やデバイスの開発に注力する新興企業の増加
  • EMEA地域における糖尿病治療とケアの改善に向けた政府の支援策
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析

第6章 糖尿病性神経障害市場治療の種類別

• 薬物
• 理学療法

第7章 糖尿病性神経障害市場障害の種類別

• 自律神経障害
• 局所神経障害
• 末梢神経障害
• 近位神経障害

第8章 糖尿病性神経障害市場：流通チャネル別

• クリニック
• 病院
• オンライン薬局
• 小売薬局

第9章 南北アメリカの糖尿病性神経障害市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の糖尿病性神経障害市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの糖尿病性神経障害市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • Neuralace Medical、糖尿病性神経障害性疼痛に対するFDA認可と画期的な非侵襲的治療への道を開く、痛みを伴う糖尿病性神経障害ラベル拡張研究（AT-PDN）の登録を完了
  • 糖尿病性末梢神経障害の早期検査の開発に140万ポンドを授与
  • ホライゾン・セラピューティクス社は、TEPEZZA（テプロツムマブ-TRBW）の適応症言語を更新し、疾患活動性や期間に関係なく甲状腺眼症（TED）患者への使用を明記することをFDAが承認したと発表しました。
  • プラエテゴ、糖尿病網膜症の新規経口薬開発のため国立眼科研究所から30万米ドルを授与
  • アボット、メドトロニック、ネブロは、末梢神経障害の治療にSCS療法を開発しています。

糖尿病患者のための糖尿病患者

• NeuroMetrixが末梢神経障害検査DPNCheck 2.0を発売
• タンデム・ダイアビティス・ケア、インスリンポンプメーカーAMFメディカルの買収を完了
• P&GヘルスとIDFが提携し、糖尿病患者の末梢神経障害に対処
• グレンマークファーマ、合併症のある糖尿病患者向けの薬を発売
• リージェンシー・ファーマシューティカルズは、糖尿病性末梢神経障害の第2相試験の登録完了と930万米ドルのシリーズB資金調達を発表しました。
• 医療技術スタートアップのYostra Labsは、慢性疾患に苦しむ患者を助けるためにシードラウンドで4億ルピーを調達しました。
• FDAが糖尿病性末梢神経障害に伴う痛みの治療にPENSデバイスを承認
• FDAは糖尿病性末梢神経障害の痛みに対するメドトロニックの神経刺激装置を承認した
• RMHはオーストラリア糖尿病イノベーション促進センターと提携しました
• ウィジングスが医療機器メーカーのインペト・メディカルを買収

第13章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. DIABETIC NEUROPATHY MARKET RESEARCH PROCESS
• FIGURE 2. DIABETIC NEUROPATHY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. DIABETIC NEUROPATHY MARKET DYNAMICS
• FIGURE 7. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. DIABETIC NEUROPATHY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 22. DIABETIC NEUROPATHY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DIABETIC NEUROPATHY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY OPIOIDS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TOPICAL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TOPICAL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY GABAPENTIN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PREGABALIN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PREGABALIN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TOPIRAMATE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TOPIRAMATE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY SEROTONIN & NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY SEROTONIN & NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY SSRIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY SSRIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TCAS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TCAS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY AUTONOMIC NEUROPATHY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY AUTONOMIC NEUROPATHY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY FOCAL NEUROPATHY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY FOCAL NEUROPATHY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PERIPHERAL NEUROPATHY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PERIPHERAL NEUROPATHY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PROXIMAL NEUROPATHY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PROXIMAL NEUROPATHY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY CLINICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY CLINICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 59. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 60. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 61. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 62. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 63. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 64. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 65. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 66. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 67. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 68. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 69. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
• TABLE 70. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
• TABLE 71. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
• TABLE 72. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
• TABLE 73. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
• TABLE 74. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
• TABLE 75. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
• TABLE 76. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
• TABLE 77. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 78. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 79. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 80. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 81. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 82. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 83. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 84. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 85. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
• TABLE 86. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
• TABLE 87. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
• TABLE 88. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
• TABLE 89. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
• TABLE 90. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
• TABLE 91. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
• TABLE 92. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
• TABLE 93. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 94. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 95. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 96. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 97. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 98. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 99. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
• TABLE 100. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
• TABLE 101. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
• TABLE 102. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
• TABLE 103. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
• TABLE 104. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
• TABLE 105. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
• TABLE 106. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
• TABLE 107. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 108. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 109. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 110. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 111. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 112. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 113. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
• TABLE 114. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
• TABLE 115. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
• TABLE 116. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
• TABLE 117. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
• TABLE 118. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
• TABLE 119. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
• TABLE 120. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
• TABLE 121. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 122. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 123. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 124. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 125. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 126. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 127. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
• TABLE 128. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
• TABLE 129. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
• TABLE 130. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
• TABLE 131. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
• TABLE 132. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
• TABLE 133. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
• TABLE 134. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
• TABLE 135. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 136. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 137. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 138. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 139. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 140. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 141. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
• TABLE 142. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
• TABLE 143. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
• TABLE 144. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
• TABLE 145. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
• TABLE 146. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
• TABLE 147. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
• TABLE 148. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
• TABLE 149. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 150. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 151. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 152. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 153. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 154. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 155. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 156. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 157. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
• TABLE 158. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
• TABLE 159. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
• TABLE 160. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
• TABLE 161. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
• TABLE 162. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
• TABLE 163. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
• TABLE 164. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
• TABLE 165. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 166. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 167. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 168. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 169. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 170. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 171. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 172. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 173. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
• TABLE 174. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
• TABLE 175. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
• TABLE 176. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
• TABLE 177. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
• TABLE 178. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
• TABLE 179. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
• TABLE 180. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
• TABLE 181. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 182. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 183. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 184. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 185. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 186. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 187. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
• TABLE 188. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
• TABLE 189. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
• TABLE 190. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
• TABLE 191. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
• TABLE 192. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
• TABLE 193. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
• TABLE 194. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
• TABLE 195. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 196. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 197. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 198. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 199. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 200. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 201. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
• TABLE 202. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
• TABLE 203. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
• TABLE 204. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
• TABLE 205. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
• TABLE 206. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
• TABLE 207. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
• TABLE 208. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
• TABLE 209. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 210. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 211. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 212. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 213. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 214. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 215. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
• TABLE 216. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
• TABLE 217. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
• TABLE 218. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
• TABLE 219. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
• TABLE 220. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
• TABLE 221. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
• TABLE 222. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
• TABLE 223. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 224. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 225. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 226. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 227. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 228. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 229. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
• TABLE 230. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
• TABLE 231. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
• TABLE 232. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
• TABLE 233. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
• TABLE 234. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
• TABLE 235. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
• TABLE 236. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
• TABLE 237. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 238. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 239. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 240. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 241. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 242. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 243. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
• TABLE 244. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
• TABLE 245. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
• TABLE 246. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
• TABLE 247. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
• TABLE 248. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
• TABLE 249. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
• TABLE 250. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
• TABLE 251. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 252. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 253. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 254. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 255. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 256. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 257. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
• TABLE 258. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
• TABLE 259. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
• TABLE 260. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
• TABLE 261. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
• TABLE 262. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
• TABLE 263. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
• TABLE 264. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
• TABLE 265. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 266. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 267. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 268. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 269. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 270. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 271. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
• TABLE 272. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
• TABLE 273. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
• TABLE 274. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
• TABLE 275. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
• TABLE 276. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
• TABLE 277. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
• TABLE 278. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
• TABLE 279. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 280. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 281. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 282. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 283. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 284. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 285. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
• TABLE 286. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
• TABLE 287. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
• TABLE 288. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
• TABLE 289. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
• TABLE 290. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
• TABLE 291. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
• TABLE 292. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
• TABLE 293. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 294. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 295. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 296. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 297. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 298. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 299. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
• TABLE 300. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
• TABLE 301. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
• TABLE 302. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
• TABLE 303. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
• TABLE 304. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
• TABLE 305. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
• TABLE 306. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
• TABLE 307. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 308. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 309. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 310. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 311. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 312. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 313. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
• TABLE 314. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
• TABLE 315. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
• TABLE 316. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
• TABLE 317. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
• TABLE 318. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
• TABLE 319. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
• TABLE 320. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
• TABLE 321. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 322. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 323. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 324. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 325. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 326. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 327. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
• TABLE 328. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
• TABLE 329. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
• TABLE 330. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
• TABLE 331. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
• TABLE 332. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
• TABLE 333. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
• TABLE 334. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
• TABLE 335. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 336. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 337. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 338. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 339. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 340. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 341. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
• TABLE 342. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MIL

[181 Pages Report] The Diabetic Neuropathy Market size was estimated at USD 3.50 billion in 2023 and expected to reach USD 3.72 billion in 2024, at a CAGR 6.37% to reach USD 5.40 billion by 2030.

Diabetic neuropathy is a medical condition that damages the nerve and occurs in patients who have diabetes. High blood sugar (glucose) can damage nerves throughout the body, and diabetic neuropathy most frequently impacts nerves in the legs and feet. The increasing need for effective treatment for diabetic neuropathy, diagnosis of diabetes, and several government initiatives are the major driving factors for the growth of the diabetic neuropathy market. In addition, the growing awareness about diabetic neuropathy, increased healthcare spending, and a rise in pharmaceutical R&D spending contribute to developing novel drugs and systems for treating diabetic neuropathy. However, the high cost of medications used to treat diabetic neuropathy and the availability of alternative therapies may limit their use by diabetic patients. Production of advanced drug delivery systems and rising research in diabetic neuropathy are leading to the development of a breakthrough system for the effective management of diabetic neuropathy conditions, accelerating their use by patients in the forecast period.

Treatment Type: Wide use of drugs for pharmacological treatment in diabetic neuropathy for alleviating pain and stabilizing nerve function

Drugs are used in the pharmacological treatment of diabetic neuropathy for alleviating pain and stabilizing nerve function. Pregabalin (Lyrica) and gabapentin (Neurontin) are popular anticonvulsant drugs for managing nerve pain in diabetic neuropathy patients. Among opioids, Tramadol (Ultram) is a centrally-acting opioid analgesic prescribed for moderate to severe pain associated with diabetic neuropathy. Physiotherapy, also known as physical therapy, is a non-pharmacological treatment that can help diabetic neuropathy patients improve their functional abilities and alleviate pain. Regular exercise and strengthening programs supervised by a certified physiotherapist can help improve muscle strength, balance, and endurance in diabetic neuropathy patients. Physiotherapy is often preferred to avoid side effects or contraindications.

Disorder Type: Preference for diabetic neuropathy due to increasing prevalence of peripheral neuropathy

Autonomic neuropathy affects the autonomic nervous system, which controls the involuntary functions of internal organs. Patients with this condition experience irregular heartbeat, urinary problems, digestive issues, and sexual dysfunction. Based on individual needs, treatments include medications to regulate blood pressure and heart rate, drugs for gastrointestinal motility, and medications to treat erectile dysfunction. Focal neuropathy is a disorder that affects a single nerve or group of nerves, causing severe pain or weakness localized in specific body parts such as hands, feet, or torso. The treatment addresses the underlying cause, such as compression or entrapment, including splinting or bracing for carpal tunnel syndrome or surgical intervention for severe cases. Peripheral neuropathy is the most common type, affecting the nerves of arms, hands, legs, and feet. Symptoms include numbness, tingling, pain, and weakness. Treatment preferences depend on individual needs, including over-the-counter pain relievers and prescription medications. Proximal neuropathy primarily affects the hip, buttock, or thigh muscles with symptoms such as severe pain and muscle weakness.

Distribution channel: Emergence of online pharmacies as a convenient distribution channel for medications prescribed for diabetic neuropathy management

Patients with diabetic neuropathy prefer clinics for convenience, affordability, and accessibility as they provide specialized care through a team of experts, including endocrinologists, podiatrists, and diabetes educators. Hospitals serve as comprehensive care providers for diabetic neuropathy patients requiring more extensive treatment or emergency interventions due to severe complications such as infections or ulcers. They offer access to equipment and multidisciplinary teams with expertise in treating complex cases. Online pharmacies have emerged as a convenient distribution channel for medications prescribed for diabetic neuropathy management, such as pain relievers, anti-seizure medications, and antidepressants. Patients prefer online pharmacies due to their ease of use, discreet delivery options, and competitive pricing compared to retail pharmacies. Retail pharmacies are popular for obtaining medications and over-the-counter supplements to manage diabetic neuropathy. They offer the advantage of face-to-face interaction with pharmacists who can provide personalized advice, medication management support, and access to a wide range of products.

Regional Insights

The Americas has a significant market in diabetic neuropathy due to the presence of a rising number of diabetic patients and increasing awareness related to diabetes disorders. Approvals from the FDA for new product development and ongoing research activities for developing novel and effective drugs are major growth factors in the Americas region. The Asia-Pacific region represents a growing landscape for the global diabetic neuropathy market due to increasing R&D activities in drug development. Several start-ups focusing on developing diabetic neuropathy treatments in the APAC region have contributed to the market growth. Government support to raise awareness regarding diabetes management and increased research and development of novel drugs and systems for relieving pain and efficient management of diabetic neuropathy conditions are creating the immense potential for the deployment of diabetic neuropathy drugs and systems in the EMEA region. Additionally, the introduction of innovative treatments and drug delivery systems is expected to contribute to the growth of the diabetic neuropathy market worldwide.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Diabetic Neuropathy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Diabetic Neuropathy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Diabetic Neuropathy Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AdventHealth, Alkem Labs, Astellas Pharma Inc., AstraZeneca PLC, Bauerfeind AG, Bayer AG, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Collegium Pharmaceutical, Inc., Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Grunenthal GmbH, Harmonium Pharma s.r.l., Lupin Limited, Medtronic PLC, Merck KGaA, NeuroMetrix, Inc., Nevro Corp., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Praetego, LLC, Regenacy Pharmaceuticals, Inc., Sanofi S.A., Stem Cell Care India, Teva Pharmaceutical Industries Ltd., The Procter & Gamble Company, Trevena, Inc., Vertex Pharmaceuticals Incorporated, Viatris Inc., and Winsantor, Inc..

Market Segmentation & Coverage

This research report categorizes the Diabetic Neuropathy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Treatment Type
  • Drugs
    • Analgesics
      • Non-Steroidal Anti-Inflammatory Drugs
      • Opioids
      • Topical

• Anticonvulsants
  • Gabapentin
  • Pregabalin
  • Topiramate

• Antidepressant
  • Serotonin & Norepinephrine Reuptake Inhibitors
  • SSRIs
  • TCAs
• Physiotherapy

• Disorder Type
  • Autonomic Neuropathy
  • Focal Neuropathy
  • Peripheral Neuropathy
  • Proximal Neuropathy

• Distribution channel
  • Clinics
  • Hospitals
  • Online Pharmacy
  • Retail Pharmacy

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Diabetic Neuropathy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Diabetic Neuropathy Market?

3. What are the technology trends and regulatory frameworks in the Diabetic Neuropathy Market?

4. What is the market share of the leading vendors in the Diabetic Neuropathy Market?

5. Which modes and strategic moves are suitable for entering the Diabetic Neuropathy Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of diabetic neuropathy and the need for effective treatment methods
    • 5.1.1.2. Increasing awareness pertaining to diagnosis & treatment of diabetes
    • 5.1.1.3. Government initiatives for the management of diabetic neuropathy
  • 5.1.2. Restraints
    • 5.1.2.1. High failure rate in clinical trials and high cost of diabetic neuropathy treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Widening diabetic neuropathy research areas
    • 5.1.3.2. Development of advanced drug delivery systems
  • 5.1.4. Challenges
    • 5.1.4.1. Complications associated with diabetic neuropathy treatment
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment Type: Wide use of drugs for pharmacological treatment in diabetic neuropathy for alleviating pain and stabilizing nerve function
  • 5.2.2. Disorder Type: Preference for diabetic neuropathy due to increasing prevalence of peripheral neuropathy
  • 5.2.3. Distribution channel: Emergence of online pharmacies as a convenient distribution channel for medications prescribed for diabetic neuropathy management
• 5.3. Market Trend Analysis
  • 5.3.1. Ongoing research for the development of novel treatments and rise in approvals for diabetic neuropathy management systems in the Americas
  • 5.3.2. Increasing prevalence of diabetes and emerging start-ups focused on developing diabetic neuropathy treatments and devices in the APAC region
  • 5.3.3. Supportive government initiatives to improve diabetes disease treatment and care in the EMEA region
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework Analysis

6. Diabetic Neuropathy Market, by Treatment Type

• 6.1. Introduction
• 6.2. Drugs
• 6.3. Physiotherapy

7. Diabetic Neuropathy Market, by Disorder Type

• 7.1. Introduction
• 7.2. Autonomic Neuropathy
• 7.3. Focal Neuropathy
• 7.4. Peripheral Neuropathy
• 7.5. Proximal Neuropathy

8. Diabetic Neuropathy Market, by Distribution channel

• 8.1. Introduction
• 8.2. Clinics
• 8.3. Hospitals
• 8.4. Online Pharmacy
• 8.5. Retail Pharmacy

9. Americas Diabetic Neuropathy Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Diabetic Neuropathy Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Diabetic Neuropathy Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Neuralace Medical Completes Enrollment of Painful Diabetic Neuropathy Label Expansion Study (AT-PDN) Paving the Way for FDA Clearance and a Breakthrough, Non-invasive Treatment for Diabetes related Neuropathic Pain
  • 12.3.2. GBP 1.4 million Awarded to Create early test for Diabetic Peripheral Neuropathy
  • 12.3.3. Horizon Therapeutics PLC announced FDA approval of an update to the indication language for TEPEZZA (teprotumumab-trbw) to specify its use in thyroid eye disease (TED) patients regardless of disease activity or duration
  • 12.3.4. Praetego awarded USD 300,000 by National Eye Institute to advance novel oral drug for diabetic retinopathy
  • 12.3.5. Abbott, Medtronic, and Nevro are developing SCS therapies to treat peripheral neuropathy treatment

a diabetic for diabetic

• 12.3.6. NeuroMetrix launched peripheral neuropathy test DPNCheck 2.0
• 12.3.7. Tandem Diabetes Care completed acquisition of insulin pump maker AMF Medical
• 12.3.8. P&G Health, IDF partnered to address Peripheral Neuropathy in people with diabetes
• 12.3.9. Glenmark Pharma launched drug for diabetic patients with comorbidities
• 12.3.10. Regenacy Pharmaceuticals announced the completion of enrollment for phase 2 Study in diabetic peripheral neuropathy & USD 9.3 million series B financing
• 12.3.11. Medtech startup Yostra Labs raised Rs 4Cr in a Seed round to help patients suffering from chronic disease
• 12.3.12. FDA Clears PENS Device for pain related to diabetic peripheral neuropathy
• 12.3.13. FDA cleared Medtronic's neurostimulator for diabetic peripheral neuropathy pain
• 12.3.14. The RMH partnered with Australian Centre for Accelerating Diabetes Innovations
• 12.3.15. Withings acquired Devicemaker Impeto Medical

13. Competitive Portfolio

• 13.1. Key Company Profiles
• 13.2. Key Product Portfolio